Procedures Resource Center Plastic Surgeon Info Contact Us Forum Blog Videos Home


XEOMIN Neurotoxin Injection

Launched in the United Kingdom in 2008, Xeomin is the third botulinum toxin type A to be promoted in the United Kingdom. Xeomin is manufactured by a German manufacturer - Mers Pharmaceuticals and has just been approved for use in the United States. 




The average first onset of action or effect is seen within four days after injection. The effect of each treatment generally lasts approximately 3-4 months; however, it may last significantly longer or shorter.

 Shelf Life of Xeomin

  • Unopened vial: 3 years

  • Reconstituted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 2 to 8C.  Technically, the product should be used immediately for best results.

  • Unopened vial: Do not store above 25C




Contraindications of Xeomin:

  • Hypersensitivity to the active substance Botulinum neurotoxin type A.

  • Generalized disorders of muscle activity (myasthenia gravis, Lambert-Eaton syndrome).

  • Presence of infection at the proposed injection site.



Xeomin should be used with caution:

  • If bleeding disorders of any type occur.

  • In patients receiving anticoagulant therapy.

  • In patients suffering from amyotrophic lateral sclerosis or other diseases which result in peripheral neuromuscular dysfunction.

  • In targeted muscles which display pronounced weakness or atrophy.





Back to BOTOX